Latest News
Foghorn Therapeutics Inc.
- Foghorn Therapeutics ends Lilly partnership, cuts 40% of staff
- Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909 | PharmExec
- Foghorn Therapeutics is cutting 40% of its workforce after Eli Lilly ends cancer drug partnership
- Why is Foghorn Therapeutics stock plunging today?
- Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
- Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
- Foghorn lays off 40% of staff after Lilly collaboration ends
- Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
- Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
- Why is Foghorn Therapeutics stock plummeting today?
- Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities
- Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation
Headlines from the last 30 days, linking to the original publishers. See all market news →